Perrigo Counts 32 Billion Reasons To Reject Mylan Offers
This article was originally published in The Tan Sheet
In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.
You may also be interested in...
Nexium 24HR’s is “the first significant milestone” Pfizer’s Rx-to-OTC strategy, says Albert Bourla, head of the division that includes consumer products. The next milestone could be a new drug application for an OTC version of Lipitor.
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
Trade group offers timeline for shift in FDA thinking about the amino acid commonly used in supplements in complaint seeking to block agency from preventing sales of NAC-containing supplements. Complaint also attests that, unlike its current stance, FDA in 1993 acknowledged NAC is lawful for use as a dietary ingredient.